Brief: Innovent Biologics Says NMPA Accepts NDA For IBI343 (Arcotatug Tavatecan)
04/06/2026 09:31
BRIEF-Innovent Biologics Says NMPA Accepts NDA For IBI343 (Arcotatug Tavatecan) June 4 (Reuters) - Innovent Biologics Inc 1801.HK:
NMPA ACCEPTS NDA FOR IBI343 (ARCOTATUG TAVATECAN) FOR ADVANCED GASTRIC CANCER
Further company coverage: 1801.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovent Biologics
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Pentagon casts dark cloud over China biotech
Innovent climbs most in a week on new drug application for gastric cancer
Brief: Innovent Biologics Says NMPA Accepts NDA For IBI343 (Arcotatug Tavatecan)
Unit of China's Haisco, Eli Lilly sign collaboration, licensing deals